摘要
目的观察N端脑钠肽前体(NT-proBNP)联合AST在急性心力衰竭(AHF)预后预测中的价值。方法 AHF患者110例,随访100d,检测血NT-proBNP、AST和血红蛋白。其中,死亡18例(A组),生存92例(B组)。结果 A组血NT-proBNP和AST高于B组(P<0.01),而血红蛋白低于B组(P<0.05)。取NT-proBNP 2379pg/ml、AST 42.15U/L和NT-proBNP联合AST预测因子0.350为临界值,其预测AHF患者发病100d内死亡的敏感度分别为84.2%、63.2%和57.9%,特异度分别为67.0%、83.0%和92.0%。AHF患者NT-proBNP与AST异常升高预示生存率低。结论联合检测NT-proBNP和AST有助于预测AHF的预后。
Objective To investigate the value of combined detection of N-terminal pro-B-type natriuretic peptide（NT-proBNP） and aspartate transaminase（AST） in predicting the prognosis of patients with acute heart failure（AHF）. Methods A total of 110 AHF patients was followed up for 100 days, during which blood levels of NT-proBNP, AST and hemoglobin were detected. During follow up,18 cases died（group A） and 92 cases were survival（group B）. Results The blood levels of NT-proBNP and AST were higher, and hemoglobin was lower, in group A than those in group B （P〈0.01 or P〈0.05）. Taking NT-proBNP 2379 pg/ml, AST 42.15 U/L and 0. 350 （as the predicting factor of NT-proBNP combined with AST） as the cutoff values, the sensitivities in predicting death of patients during the follow-up of 100 days were 84. 2%, 63.2% and 57.9%, and the specificities were 67.0%, 83. 0% and 92.0%, respectively. Abnormally higher levels of NT-proBNP and AST predicted poor survival rate of patients with AHF. Conclusion Combined detection of NT-proBNP and AST is helpful in predicting the prognosis of patients with AHF.
出处
《江苏医药》
CAS
2015年第15期1771-1773,共3页
Jiangsu Medical Journal
基金
"十二五"科技支撑计划(2011BAI11B08)
